User menu

Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Bibliographic reference Debucquoy, Annelies ; Goethals, Laurence ; Libbrecht, Louis ; Perneel, Christiaan ; Geboes, Karel ; et. al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.. In: International Journal of Colorectal Disease : clinical and molecular gastroenterology and surgery, Vol. 24, no.2, p. 129-138 (2008)
Permanent URL http://hdl.handle.net/2078/187440
  1. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P (1994) Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344:707–711
  2. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 133:894–899
  3. Wibe A, Eriksen MT, Syse A, Myrvold HE, Soreide O (2003) Total mesorectal excision for rectal cancer—what can be achieved by a national audit? Colorectal Disease 5:471–477
  4. Hermanek P, Hermanek PJ (2000) Role of the surgeon as a variable in the treatment of rectal cancer. Semin Surg Oncol 19:329–335
  5. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646
  6. Krook James E., Moertel Charles G., Gunderson Leonard L., Wieand Harry S., Collins Roger T., Beart Robert W., Kubista Theodore P., Poon Michael A., Meyers William C., Mailliard James A., Twito Donald I., Morton Roscoe F., Veeder Michael H., Witzig Thomas E., Cha Stephen, Vidyarthi Subhash C., Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma, 10.1056/nejm199103143241101
  7. Lee JH, Lee JH, Ahn JH, Bahng H, Kim TW, Kang YK, Lee KH, Kim JC, Yu CS, Kim JH et al (2002) Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 20:1751–1758
  8. O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507
  9. Stockholm Rectal Cancer Study Group (1990) Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 66:49–55
  10. Tepper JE, O’Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB III, Cummings B, Gunderson LL, Macdonald JS, Martenson JA (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 15:2030–2039
  11. Thomas PR, Lindblad AS (1988) Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 13:245–252
  12. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
  13. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254–266
  14. Willett CG, Kozin SV, Duda DG, di TE, Kozak KR, Boucher Y, Jain RK (2006) Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33:S35–S40
  15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715
  16. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40:2–11
  17. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
  18. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721–729
  19. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567–572
  20. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199:221–228
  21. de Bruin EC, vand V, van de PS, Nagtegaal ID, van Krieken JH, Gosens MJ, Peltenburg LT, Medema JP, Marijnen CA (2006) Prognostic value of apoptosis in rectal cancer patients of the Dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 12:6432–6436
  22. Marijnen CA, Nagtegaal ID, Mulder-Stapel AA, Schrier PI, van,d V, van Krieken JH, Peltenburg LT (2003) High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 57:434–443
  23. Ivanov Sergey, Liao Shu-Yuan, Ivanova Alla, Danilkovitch-Miagkova Alla, Tarasova Nadezhda, Weirich Gregor, Merrill Marsha J., Proescholdt Martin A., Oldfield Edward H., Lee Joshua, Zavada Jan, Waheed Abdul, Sly William, Lerman Michael I., Stanbridge Eric J., Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer, 10.1016/s0002-9440(10)64038-2
  24. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH et al (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083
  25. Saarnio Juha, Parkkila Seppo, Parkkila Anna-Kaisa, Haukipuro Kari, Pastoreková Silvia, Pastorek Jaromir, Kairaluoma Matti I., Karttunen Tuomo J., Immunohistochemical Study of Colorectal Tumors for Expression of a Novel Transmembrane Carbonic Anhydrase, MN/CA IX, with Potential Value as a Marker of Cell Proliferation, 10.1016/s0002-9440(10)65569-1
  26. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23
  27. Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, Suriawinata A, Paty PB, Minsky BD, Weiser MR et al (2004) Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28:215–223
  28. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel quasi-viral agent, MaTu, is a two-component system. Virology 187:620–626
  29. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dorken B, Daniel PT (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391–3401
  30. Dent P., Reardon D. B., Park J. S., Bowers G., Logsdon C., Valerie K., Schmidt-Ullrich R., Radiation-induced Release of Transforming Growth Factor alpha Activates the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway in Carcinoma Cells, Leading to Increased Proliferation and Protection from Radiation-induced Cell Death, 10.1091/mbc.10.8.2493
  31. Ruifrok AC, Mason KA, Lozano G, Thames HD (1997) Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor beta 1–3 and their receptors in mouse jejunum after radiation treatment. Radiat Res 147:1–12
  32. Schmidt-Ullrich Rupert K., Valerie Kristoffer C., Chan Winnie, McWilliams Dena, Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures, 10.1016/0360-3016(94)90570-3
  33. Steinauer Kirsten K, Gibbs Iris, Ning Shoucheng, French John N, Armstrong Jeff, Knox Susan J, Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells, 10.1016/s0360-3016(00)00671-4
  34. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID (2007) Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 13:6617–6623
  35. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45:895–903
  36. Jass JR (1987) The pathological classification of colorectal cancer. Ann Acad Med Singapore 16:469–473
  37. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P (2005) Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 11:4754–4760
  38. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S (2002) Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 19:527–534
  39. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064–4068
  40. Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254–1257
  41. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K (2004) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10:8465–8471
  42. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y, Nagawa H (2000) Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83:324–328
  43. Joo YE, Kim HS, Min SW, Lee WS, Park CH, Park CS, Choi SK, Rew JS, Kim SJ (2002) Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 31:147–154
  44. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W (2002) COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 22:1225–1230
  45. Wu Ai-Wen, Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients’ prognosis, 10.3748/wjg.v9.i9.1990
  46. Zhang H, Sun XF (2002) Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97:1037–1041
  47. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R (1999) Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes’ stage B colorectal cancers. Br J Cancer 79:577–581
  48. Chen YT, Henk MJ, Carney KJ, Wong WD, Rothenberger DA, Zheng T, Feygin M, Madoff RD (1997) Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index. J Gastrointest Surg 1:266–272
  49. Sato T, Nishimura G, Fushida S, Fujimura T, Yonemura Y, Nonomura A, Miwa K, Miyazaki I (1998) Evaluation of p53, Ki-67 and DNA ploidy in both primary rectal carcinomas and locally recurrent tumors. Oncol Rep 5:1225–1229
  50. Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, Leung DH, Paty PB, Klimstra D, Cordon-Cardo C, Wong WD (2002) Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 8:3841–3849
  51. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O’Connell MJ, Levitt R et al (2002) Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735–1743
  52. Jansson A, Sun XF (1997) Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 105:730–734
  53. Rosati G, Chiacchio R, Reggiardo G, De SD, Manzione L (2004) Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 25:258–263